Cleveland Clinic 29th Annual Diabetes Day 2025
+ Include: 16 videos + 20 pdfs, size: 5.35 GB
+ Target Audience: endocrinologists, diabetes educators
+ Information:
The 29th Annual Diabetes Day: Therapeutics, Technology and Surgery is presented by the Cleveland Clinic Department of Endocrinology, Diabetes and Metabolism to provide up-to-date reviews of management strategies and research on the complications of diabetes. Key topic areas that will be addressed include:
- Review of therapeutic options to manage both Type 1 and 2 diabetes and their complications, including a pump update, and new insulins and continuous glucose monitoring updates.
- Importance of maintaining muscle mass during obesity management.
- Latest technology in insulin pumps
- New roles for GLP1 receptor agonists SGLT-2 inhibitors and mineralocorticoid receptor antagonists
- Complications of GLP-1 receptor agonists
This year’s curriculum will also feature discussions about:
- Glucose variability and diabetes
- Effects of high fat and high protein diets on glucose control
- Effects of GLP-1 on sleep apnea
- Nutritional supplements in treatment of DM2
The goal of this symposium is to increase practitioners’ competence and clinical performance in treating diabetes and its complications and, ultimately, to improve patient outcomes.
Attendees will be able to:
- Critically appraise clinical evidence and guidelines supporting hybrid closed-loop systems in pregnancy and identify key considerations when initiating and monitoring hybrid closed-loop pumps during pregnancy.
- Describe the efficacy of inhaled insulin to insulin pump therapy in diabetes management.
- Discuss the role of nutritional supplements in the management of Type 2 diabetes and glycemic control, including the use of berberine.
- Discuss future directions and challenges in developing and implementing oral GLP-1 agonists and multi-agonist therapy in diabetes care and summarize clinical evidence on the incidence and risk of gastroparesis, pancreatitis, and thyroid cancer associated with GLP-1 agonist use.
- Analyze current research and define treatment strategies for challenges in diabetes care, including dementia, blood pressure, including intensive blood pressure control, and cardiovascular and renal complications in diabetes.
- Discuss evidence-based treatment strategies for post-gastric bypass hypoglycemia, including dietary modifications, pharmacotherapy, and other interventions.
- Discuss practical considerations for initiating and titrating novel therapies such as efsitora alfa in different patient populations, including those with complex diabetes management needs.
Who should attend?
This activity is designed for physicians, diabetes educators, nurses, nurse practitioners, pharmacists, pharmacy technicians, physician assistants, residents and fellows, and other health care professionals who care for patients with diabetes.
+ Topics:
Thursday, May 22, 2025 All times in Eastern Time |
|
|
7:00 am
|
Registration and Exhibits |
|
7:15 am
|
Non-CME Breakfast Session |
|
7:55 am
|
Welcome and Introduction Robert Zimmerman, MD |
|
8:00 am
|
New Technology: Equity and Access Sarah Macleish, DO |
|
8:30 am
|
Use of Hybrid Closed Loop Pumps in Pregnancy in DM 1 and DM 2 Kevin Borst, DO |
|
8:50 am
|
Preventing Type 2 Diabetes: Current Management of Pre Diabetes Oscar Morey Vargus, MD |
|
9:10 am
|
Nutritional Supplements in Treatment of DM 2: Focus on Berberine Keren Zhou, MD |
|
9:30 am
|
Oral GLP-1 Receptor Agonists and Multi Agonist Therapy Robert Zimmerman, MD |
|
10:00 am
|
Refreshment Break and Exhibits |
|
10:15 am
|
Increased Risk of Demetia in Patients with Diabetes and How to Prevent Willy Valencia Rodrigo, MD |
|
10:35 am
|
Effect of Intensive BP Control in Diabetes. New insights from BP ROAD Dennis Bruemmer, MD, PhD |
|
11:00 am
|
Treatment of Post Gastric Bypass Hypoglycemia Lina Alkhaled, MD |
|
11:30 am
|
Complications of GLP-1 Receptor Agonists: Gastroparesis, Pancreatitis, Thyroid Cancer: What is the Data? Kevin Pantalone, DO |
|
12:00 pm
|
Ultra Long-acting Insulins Focus on Efsitora Alpha Ravali Veeramachaneni, MD |
|
12:30 pm
|
Concurrent Non-CME Lunch Presentations |
|
1:30 pm
|
Use of Insulin Pumps; Innovations in the Last Year Diana Isaacs, PharmD |
Concurrent Workshops2:05 pm Workshop 1 – CGM Workshop Cecilia Lansang, MD Kevin Malloy, DO Diana Isaacs, PharmD 2:05 pm Workshop 2 – Diabetes Distress: Simulation and Discussion Emily Durfey, MSW, LSW Stephanie Ash, MSW, LSW Keysha Ramsey, BSW, LSW 2:05 pm Workshop 3 – Prevention of Exercise Induced Hypoglycemia: Metoclopramide and Low Dose Glucagon Mona Gossman, MD 2:35 pm Screening for Diabetes Related Antibodies for Prevention of Type 1 Diabetes Leann Olansky, MD |
|
|
3:05 pm
|
Refreshment Break and Exhibits |
|
3:20 pm
|
Preserving Muscle Mass with Weight Loss with High Protein Diet Marcio Griebeler, MD |
|
3:45 pm
|
Implications of Glucose Variability on Chronic Complications of Diabetes Adi Mehta, MD |
|
4:15 pm
|
Effect of GLP-1/GIP Agonists on Sleep Apnea Marwan Hamaty, MD |
|
4:45 pm
|
MASH, NASH, NAFLD, MASLD: Who to Screen, How to Treat , When to Refer Yael Mauer, MD |
|
5:15 pm
|
Adjourn/Non-CME Reception |
